Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ovid Therapeutics Inc (NQ: OVID )

1.031 +0.093 (+9.88%)
Streaming Delayed Price Updated: 3:21 PM EDT, Jul 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ovid Therapeutics Inc

< Previous 1 2 Next >
Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts
Via Benzinga
Nasdaq Surges Over 200 Points; Aaron's Shares Jump
Via Benzinga
Is the Stock Market Closed on Juneteenth 2024?
Investors wondering if the stock market is closed on Juneteenth 2024 have come to the right place as we have an answer to that question! 
Via InvestorPlace
ACHR Stock Alert: Archer Aviation Strikes New Deal With Signature Aviation
Archer Aviation stock is down on Monday after the company alerted ACHR investors to a new MOU signed with Signature Aviation. 
Via InvestorPlace
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Ovid Therapeutics
Via Benzinga
AAN Stock Alert: The Aaron’s Company Pops 33% on Take-Private Deal
The Aaron's Company stock is up on Monday after it announced a take-private deal that values AAN shares at $10.10 each. 
Via InvestorPlace
Why Is Ovid Therapeutics (OVID) Stock Down 69% Today?
Ovid Therapeutics stock is down on Monday with heavy trading of OVID shares after the company reported a failed Phase3 clinical trial. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Rises 1%; Mustang Bio Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
US Stocks Mixed; Dow Tumbles Over 100 Points
Via Benzinga
Topics Stocks
Exposures US Equities
Recap: Ovid Therapeutics Q4 Earnings
Via Benzinga
Ovid Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Ovid Therapeutics: Q1 Earnings Insights
Via Benzinga
Looking Into Ovid Therapeutics's Return On Capital Employed
Via Benzinga
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug. 
Via Benzinga
Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
3 Sorry Penny Stocks to Sell in May While You Still Can
Steer clear of these three penny stocks to sell that are plagued by financial instability and mounting losses. 
Via InvestorPlace
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024
Although the concept of penny stocks to buy is extremely risky, these ideas have the advantage of analysts’ positive assessments. 
Via InvestorPlace
OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q1 2024
OVID stock results show that Ovid Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Over $2M Bet On NextNav? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones index closed higher by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Very Promising Penny Stocks That Are Flying Under the Radar
Although the very concept of penny stocks to buy screams risk, these ideas just might be intriguing enough for speculators. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023
Via Benzinga
The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech
One executive called this the most "damaging" decision in five decades. 
Via Investor's Business Daily
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this... 
Via Benzinga
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating... 
Via Benzinga
Drugmakers Stand Up for Reproductive Rights: Pfizer and Biogen Among 300 Condemning Abortion Pill Approval Suspension
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 94 companies set new 52-week lows. 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.